quinazolines has been researched along with Sepsis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z; Min, W; Ni, W; Pierce, RW; Yin, M; Zhang, H; Zhou, HJ | 1 |
| Brown-Driver, V; Cunningham, ML; Finn, J; Hilgers, MT; Hough, G; Kwan, BP; Lam, T; Nelson, KJ; Ong, V; Shaw, KJ; Trzoss, M | 1 |
| Cha, JH; Cho, NC; Kim, D; Kim, H; Kim, T; Kim, YK; Kwak, J; Lee, J; Lee, KT; No, KT; Pae, AN; Park, KD; Seo, SH; Shin, JS | 1 |
| Daiber, A; Daub, S; Gori, T; Grabbe, S; Hausding, M; Karbach, S; Klein, T; Knorr, M; Kossmann, S; Kröller-Schön, S; Münzel, T; Oelze, M; Schell, R; Scholz, A; Schuff, A; Schulz, E; Sudowe, S; Wenzel, P | 1 |
| Abacioglu, N; Altug, S; Demirkay, B; Tunçtan, B; Uludag, O | 1 |
| Beutel, G; Cassidy, J; Chick, J; Gill, S; Glen, H; Schöffski, P; Twelves, C | 1 |
| Evans, TR; Fullarton, GM; Garcia-Vargas, J; Harris, AL; Lofts, FJ; Mackay, HJ; McDonald, AC; McInnes, A; Paul, J; Raby, N; Soukop, M | 1 |
2 trial(s) available for quinazolines and Sepsis
| Article | Year |
|---|---|
Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Deoxyuridine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Genotype; Glutarates; Homocysteine; Humans; Infusions, Intravenous; Isoindoles; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polymorphism, Genetic; Quinazolines; Sepsis; Thymidylate Synthase; Time Factors; Treatment Outcome | 2005 |
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Hypersensitivity; Enteritis; Epirubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pulmonary Embolism; Quinazolines; Sepsis; Stomach Neoplasms; Survival Analysis; Thiophenes; Treatment Outcome | 2001 |
5 other study(ies) available for quinazolines and Sepsis
| Article | Year |
|---|---|
BMX Represses Thrombin-PAR1-Mediated Endothelial Permeability and Vascular Leakage During Early Sepsis.
Topics: Animals; Capillary Permeability; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Mice, Inbred C57BL; Mice, Knockout; Permeability; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Receptor, PAR-1; Sepsis; Signal Transduction; Thrombin | 2020 |
Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines.
Topics: Animals; Anti-Bacterial Agents; Benzimidazoles; Drug Resistance, Bacterial; Folic Acid Antagonists; Humans; Mice; Microbial Sensitivity Tests; Models, Molecular; Quinazolines; Sepsis; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2014 |
Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists.
Topics: Amination; Animals; Anti-Inflammatory Agents; Cell Line; Dinoprostone; Interleukin-1beta; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; NF-kappa B; Quinazolines; Receptor, PAR-2; Sepsis; Tumor Necrosis Factor-alpha | 2015 |
Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Topics: Administration, Oral; Animals; Antioxidants; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Leukocytes; Linagliptin; Lipopolysaccharides; Male; Neutrophils; Oxidative Stress; Purines; Quinazolines; Rats; Rats, Wistar; Respiratory Burst; Sepsis; Vasodilation | 2012 |
Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis.
Topics: 6-Ketoprostaglandin F1 alpha; Analysis of Variance; Animals; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Female; Furans; Lipopolysaccharides; Male; Mice; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Quinazolines; Sepsis; Sulfonamides | 2003 |